YOVO VAPE Unveils Customizable Flavor E-Cigarette with Adjustable Nicotine Levels and Six Ice Settings

Market by 2FIRSTS
Dec.24.2024
YOVO VAPE Unveils Customizable Flavor E-Cigarette with Adjustable Nicotine Levels and Six Ice Settings
YOVO VAPE introduces innovative e-cigarette STARWALK 40K, featuring adjustable nicotine and cooling levels for a unique vaping experience.

Special announcement:

This article is for internal industry communication only and does not make any recommendations for brands or products.

The images shown in this article are for descriptive purposes only and are not intended as advertisements for any product.

This article prohibits access to minors.


 

2Firsts observed that as American taste preferences continue to evolve, e-cigarette brands like YOVO VAPE have recently introduced innovative products such as the STARWALK 40K. This e-cigarette stands out for its icy coolness, nicotine adjustment function, and a long-lasting experience of up to 40,000 puffs.

 

More specifically, the product specifications of the Yovo Starwalk 40K are shown in the table below.

 

YOVO VAPE Unveils Customizable Flavor E-Cigarette with Adjustable Nicotine Levels and Six Ice Settings
Yovo Starwalk 40K Parameters | Drawing: 2Firsts

 

The main features of STARWALK 40K are that users can activate the display screen by touch and adjust the levels of nicotine and coolness. The nicotine concentration is adjustable in three levels - low, regular, and strong, with the highest nicotine concentration being 5%; the coolness level has six adjustable levels, including no coolness, chilled, cool, icy, frosty, and freezing.

 

YOVO VAPE Unveils Customizable Flavor E-Cigarette with Adjustable Nicotine Levels and Six Ice Settings
Yovo Starwalk 40K | Image Source: YOVO VAPE Official Website

 

According to information on the official website of the YOVO VAPE brand, the brand is headquartered in New York, USA. Currently, the website displays three disposable e-cigarette products, including the STARWALK 40K.

 

YOVO VAPE Unveils Customizable Flavor E-Cigarette with Adjustable Nicotine Levels and Six Ice Settings
YOVO VAPE Brand Information | Image source: YOVO VAPE official website

 

According to representatives from 2Firsts at the 2023 Russian e-cigarette exhibition, the brand is positioned as a joint operation between personnel from China and Russia.

 

At the end of 2023, the brand will debut at the Russian e-cigarette exhibition (VAPE CLUB SHOW 2023); in March of this year, YOVO's brand RAMA launched the Bluetooth e-cigarette product RAMA 16000. 

 

Yovo Starwalk 40K has now landed on several e-cigarette distributor websites in the United States such as vapesourcing, generalvape, vapewholesaleusa and vaping360. The product is priced at around $16.99.

 

YOVO VAPE Unveils Customizable Flavor E-Cigarette with Adjustable Nicotine Levels and Six Ice Settings
Yovo Starwalk 40K Product Information | Image source: vaping360

 


2Firsts will continue to monitor the performance and market trends of e-cigarette products worldwide, providing the public with accurate and authoritative industry information.

 

2FIRSTS is a product column dedicated to providing readers with the latest information on new products in the tobacco industry. In an effort to gather and share first-hand information from the industry, 2FIRSTS welcomes readers to submit articles and share the newest products in the e-cigarette field.

 

If you have any unique insights or information, please feel free to contact us at info@2firsts.com at any time.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Krishnamoorthi Questions FDA Over Planned PMTA Rewrite, Seeks Communications With Altria and Reynolds
U.S. Rep. Raja Krishnamoorthi on Oct. 6 questioned the FDA over its plan to reassess and potentially replace the 2021 PMTA regulatory framework, asking the agency to identify provisions it may change or eliminate, state whether current scientific evidentiary standards will be maintained, and disclose communications with Altria, Reynolds and other parties challenging the rule. Krishnamoorthi led a congressional investigation into JUUL and youth vaping in 2019 and has since remained active on e-cigarette regulation and enforcement.
Regulations
Oct.08
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona Turns to a 50% Retail Vape Tax as Tobacco Tax Revenue Falls 47% From 2008
Arizona's First Things First is pushing for an excise tax equal to 50% of the retail price of vaping products, estimating that the measure could generate about $100 million annually. The agency says its tobacco-tax revenue has fallen 47% from 2008 levels. Arizona has attempted to broaden its nicotine tax base in each of the past two years: a 2025 bill proposed a 50% wholesale-price tax, while a 2026 measure shifted to a 50% retail-price tax covering alternative nicotine products and vapor products. Separately, the state enacted HB 4001 this year to establish a new licensing and sales framework for alternative nicotine products.
Sep.21
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07